| Literature DB >> 35493309 |
Virág Demján1,2,3, Andrea Sója1,2,3, Tivadar Kiss2,4, Alexandra Fejes1,2,3, Flóra Diána Gausz1,2,3, Gergő Szűcs1,2,3, Andrea Siska5, Imre Földesi5, Roland Tengölics6,7, Zsuzsanna Darula8,9, Dezső Csupor2,4,10,11, Márton Pipicz1,2,3, Tamás Csont1,2,3.
Abstract
Background and aim: Common chickweed (Stellaria media) tea has traditionally been applied for treatment of various metabolic diseases including diabetes in folk medicine; however, experimental evidence to support this practice is lacking. Therefore, we aimed to assess the effect of Stellaria media tea on glucose homeostasis and cardiac performance in a rat model of diabetes. Experimental procedure: Hot water extract of Stellaria media herb were analyzed and used in this study, where diabetes was induced by fructose-enriched diet supplemented with a single injection of streptozotocin. Half of the animals received Stellaria media tea (100 mg/kg) by oral gavage. At the end of the 20-week experimental period, blood samples were collected and isolated working heart perfusions were performed. Results and conclusion: Compared to the animals receiving standard chow, serum fasting glucose level was increased and glucose tolerance was diminished in diabetic rats. Stellaria media tea did not affect significantly fasting hyperglycemia and glucose intolerance; however, it attenuated diabetes-induced deterioration of cardiac output and cardiac work. Analysis of the chemical composition of Stellaria media tea suggested the presence of rutin and various apigenin glycosides which have been reported to alleviate diabetic cardiomyopathy. Moreover, Stellaria media prevented diabetes-induced increase in cardiac STAT3 phosphorylation. We demonstrated for the first time that Stellaria media tea may beneficially affect cardiac dysfunction induced by diabetes without improvement of glucose homeostasis. Rutin and/or apigenin glycosides as well as modulation of STAT3 signaling may be implicated in the protection of Stellaria media tea against diabetic cardiomyopathy.Entities:
Keywords: Diabetic co-morbidity; Flavonoid; Medicinal herb; Prevention; Signal transducer and activator of transcription 3
Year: 2021 PMID: 35493309 PMCID: PMC9039105 DOI: 10.1016/j.jtcme.2021.08.003
Source DB: PubMed Journal: J Tradit Complement Med ISSN: 2225-4110
Fig. 1Experimental protocol: rats were divided into Control, Diabetes and Diabetes + Stellaria media groups receiving either a standard chow or a chow supplemented with 60% fructose, respectively, for 20 weeks (A). Fasting blood glucose measurement was performed every four weeks until week 16. Oral glucose tolerance test (OGTT) was performed on week 12, 16 and 19. At week 17, rats in the Diabetes and Diabetes + Stellaria media groups were injected with a low-dose streptozotocin (20 mg/kg body weight) intraperitoneally. Fasting blood glucose was measured on week 18 and 19 to monitor the effect of streptozotocin injection. On week 20, the animals were anaesthetised and sacrificed. Blood samples were collected from the abdominal aorta, hearts were isolated and subjected to working heart perfusion according to Neely (A). Body weight (B) and weight gain (C) during 20 weeks in the Control group (circles), Diabetes group (squares) and Diabetes + Stellaria media group (triangles). Results are means ± SEM (n = 8–10), analyzed by repeated measures two-way ANOVA or one-way ANOVA with Holm-Sidak post hoc test,∗p < 0.05 Diabetes vs. Control.
Fig. 2Fasting blood glucose levels (A) and area under the curve (AUC) (B) values of oral glucose tolerance tests (OGTT) measurements. Results are means ± SEM (n = 8–10), analyzed by one-way ANOVA followed by Holm-Sidak post hoc test,∗p < 0.05 vs. Control, #p < 0.05 vs. Diabetes.
Fig. 3Parameters representing pancreatic function at week 20: fasting blood glucose at termination (A), HbA1c levels (B), serum insulin levels (C), pancreas weight (D), enzyme activities of α-amylase (E) and lipase (F). Results are means ± SEM (n = 8–10 except for serum insulin measurement where n = 6–8), analyzed by one-way ANOVA followed by Holm-Sidak post hoc test,∗p < 0.05 vs. Control.
Serum parameters representing liver and kidney function, cardiac markers, lipid panel and electrolytes.
| Control | Diabetes | Diabetes + | ||
|---|---|---|---|---|
| ALAT (U/L) | 34.7 ± 2.0 | 23.9 ± 2.2∗ | 29.1 ± 2.5 | <0.05 |
| ASAT (U/L) | 65.1 ± 2.5 | 50.4 ± 1.8∗ | 55.6 ± 1.9∗ | <0.05 |
| ALP (U/L) | 46.9 ± 1.9 | 86.5 ± 12.7∗ | 101.4 ± 10.4∗ | <0.05 |
| Albumin (g/L) | 40.8 ± 0.8 | 41.8 ± 0.6 | 42.0 ± 0.4 | ns |
| Total protein (g/L) | 54.0 ± 1.5 | 55.9 ± 0.4 | 57.3 ± 0.7∗ | <0.05 |
| Urea (mmol/L) | 6.3 ± 0.3 | 3.8 ± 0.7∗ | 3.8 ± 0.3∗ | <0.05 |
| Creatinine (μmol/L) | 32.1 ± 1.3 | 35.3 ± 1.8 | 35.2 ± 1.6 | ns |
| CK (U/L) | 276.9 ± 25.7 | 235.1 ± 19.4 | 289.7 ± 29.8 | ns |
| CK-MB (U/L) | 438.6 ± 29.1 | 433.8 ± 37.9 | 524.8 ± 55.6 | ns |
| LDH (U/L) | 281.7 ± 26.0 | 298.4 ± 23.3 | 359.3 ± 42.9 | ns |
| Cholesterol (mmol/L) | 1.58 ± 0.05 | 1.74 ± 0.16 | 1.78 ± 0.11 | ns |
| HDL-Cholesterol (mmol/L) | 0.95 ± 0.04 | 1.03 ± 0.08 | 1.08 ± 0.10 | ns |
| Sodium (mmol/L) | 142.1 ± 0.9 | 141.5 ± 0.9 | 140.2 ± 1.1 | ns |
| Potassium (mmol/L) | 4.8 ± 0.1 | 5.1 ± 0.1 | 5.1 ± 0.2 | ns |
| Chloride (mmol/L) | 101.9 ± 0.5 | 101.3 ± 0.8 | 101.0 ± 0.5 | ns |
Results are means ± SEM (n = 8–10), analyzed by one-way ANOVA followed by Holm-Sidak post hoc test,∗p < 0.05 vs. Control. ALP alkaline phosphatase, ALAT alanine aminotransferase, ASAT aspartate aminotransferase, CK creatine kinase, CK-MB creatine kinase – myocardial band, HDL high-density lipoprotein cholesterol, LDH lactate dehydrogenase, ns non-significant.
Fig. 4Cardiac function in isolated hearts subjected to working perfusion according to Neely: cardiac output (A), cardiac work (B), left ventricular end diastolic pressure (LVEDP) (C). Results are means ± SEM (n = 8–10), analyzed by one-way ANOVA followed by Holm-Sidak post hoc test,∗p < 0.05 vs. Control, #p < 0.05 vs. Diabetes.
Parameters measured by working heart perfusion according to Neely.
| Control | Diabetes | Diabetes + | ||
|---|---|---|---|---|
| Aortic flow (mL) | 44.4 ± 2.6 | 27.3 ± 2.4∗ | 34.4 ± 2.3∗ | p < 0.05 |
| Coronary flow (mL) | 22.8 ± 0.7 | 21.8 ± 1.5 | 23.7 ± 1.0 | ns |
| Max dp/dt (mmHg/s) | 6323 ± 282 | 6260 ± 439 | 6431 ± 487 | ns |
| Min dp/dt (mmHg/s) | – 4520 ± 188 | – 4512 ± 397 | – 4496 ± 374 | ns |
| Aortic diastolic pressure (mmHg) | 37.6 ± 0.5 | 37.9 ± 0.8 | 37.8 ± 1.1 | ns |
| Aortic systolic pressure (mmHg) | 114.8 ± 2.5 | 110.4 ± 3.3 | 114.9 ± 3.1 | ns |
| LVDP (mmHg) | 136.2 ± 4.6 | 130.0 ± 4.5 | 131.3 ± 5.2 | ns |
| Heart rate (1/min) | 240 ± 10 | 211 ± 16 | 231 ± 11 | ns |
Results are means ± SEM (n = 8–10), analyzed by one-way ANOVA with Holm-Sidak post hoc test,∗p < 0.05 vs. Control. LVDP left ventricular developed pressure, ns non-significant.
Fig. 5Western blot analysis of phosphorylation of proteins: signal transducer and activator of transcription 3 (STAT3) (A), protein kinase B (Akt) (B), extracellular signal-regulated kinase (Erk) (C), proapoptotic Bax (D), representative bands (E), antiapoptotic Bcl-XL (F). Results are means ± SEM (n = 7), analyzed by one-way ANOVA followed by Fisher LSD post hoc test,∗p < 0.05 vs. Control, #p < 0.05 vs. Diabetes.